Amarantus BioScience (AMBS) 10-K2015 FY Annual report

Filed: 16 May 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: abandonment, accredited, affiliated, AMDX, Arendt, Argot, Army, artery, asequencing, attached, Avant, breakthrough, Brog, Buyer, buyout, Carlo, category, Cayman, Chardan, chattel, Congenital, covert, CRADA, deed, deferral, Delafield, depict, dual, duly, eighteen, eighty, embodied, encourage, evidenced, exit, fifteen, finite, foreclose, foregoing, GCMN, Genovese, Giant, Gluck, hereto, horizon, hundred, Imputation, infection, Infusion, Jersey, Keelin, leak, Leinwand, lessee, Melanocytic, millionfor, Monte, mortality, MSPreciseperformed, MSPrecise®diagnostic, Nevi, notified, notion, occlusion, ODD, OID, OTC, OTCQX, Pan, paper, passage, paused, pediatric, pigmentosaor, Pledged, possession, PP, print, priority, Prof, proportionally, proportionately, proprietorship, Provista, purport, quantitative, quotation, quotient, radiation, RAO, ratchet, ratio, reacquisition, relapsed, remitting, retroactive, Robinson, RPDD, sense, simulation, slightly, subset, TBSA, Theranostic, thereunto, therewith, thousand, threatening, tier, topline, traditional, transition, unaudited, unclear, undersigned, undiscounted, Unpublished, unrealized, unregistered, upcoming, usable, USAISR, valuable, Walkerville

Removed: barrier, complementary, compound, computer, connected, created, defaulted, Delaware, derived, detect, disbursed, disposed, estate, executed, final, formally, half, higher, importantly, inclusive, indirectly, ineffective, inherent, initiate, Integrated, joined, joint, MDx, network, portfolio, priced, promising, range, regular, representing, restriction, restructuring, schedule, Sponsoring, stroke, supported, transferred, Treadway

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

AMBS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this annual report of Amarantus BioScience Holdings, Inc. (the “Registrant”) on Form 10-K for the period ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(a) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(b) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: May 16, 2016

/s/ GERALD E. COMMISSIONG

Gerald E. Commissiong

Chief Executive Officer

(Principal Executive Officer)